Pancreatic cancer patients who underwent chemotherapy both before and after surgery had longer survival rates compared to those who received...
Vous n'êtes pas connecté
An analysis of data from a randomised clinical trial for patients with stage 3 colon cancer found that those with PIK3CA mutations who took celecoxib, an anti-inflammatory drug, after surgery lived significantly longer and had longer disease-free survival compared to those without the mutation. The study, highlighting a potential breakthrough in personalised cancer treatment, was [...]
Pancreatic cancer patients who underwent chemotherapy both before and after surgery had longer survival rates compared to those who received...
Patients with pancreatic cancer who received chemotherapy both before and after surgery experienced longer survival rates than would be expected from...
THURSDAY, June 27, 2024 -- PIK3CA mutational status may be beneficial for predicting response to addition of the cyclooxygenase 2 (COX-2) inhibitor...
A new study published in JAMA Network Open by an international cohort of researchers provides the latest data on the effectiveness of treating...
FRIDAY, June 28, 20204 (HealthDay news) -- An immunotherapy/chemotherapy combo drug can help early-stage breast cancer patients remain cancer-free...
FRIDAY, June 28, 20204 (HealthDay news) -- An immunotherapy/chemotherapy combo drug can help early-stage breast cancer patients remain cancer-free...
FRIDAY, June 28, 20204 (HealthDay news) -- An immunotherapy/chemotherapy combo drug can help early-stage breast cancer patients remain cancer-free...
Researchers have discovered metabolic markers that forecast cancer patients' immunotherapy responses and survival outcomes, highlighting the...
Clinical stage biotechnology company PharmAust has received commitments to raise $10 million via an institutional placement with directors and...
Adding an anti-inflammatory drug to anti-PD1 checkpoint inhibitor immunotherapy has shown great promise as a new strategy against advanced lung...